Warfarin embryopathy: patient, possibility, pathogenesis and prognosis.
de Vries
T W
TW
Department of Pediatrics, Medical Centre Leeuwarden, The Netherlands.
van der Veer
E
E
Heijmans
H S
HS
D000074:Acenocoumarol / Q000009:adverse effects*; D001842:Bone and Bones / Q000002:abnormalities; D002658:Developmental Disabilities / Q000139:chemically induced; D004338:Drug Combinations; D005260:Female; D005315:Fetal Diseases / Q000139:chemically induced*; D005865:Gestational Age; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use; D007231:Infant, Newborn; D007741:Labetalol / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D011239:Prednisolone / Q000627:therapeutic use; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D011379:Prognosis; D012307:Risk Factors
D004338:Drug Combinations; D006852:Hydrochlorothiazide; D011239:Prednisolone; D000074:Acenocoumarol; D007741:Labetalol